Session 106
Bayer and Evotec - From a Single Alliance to a Truly Preferred Partnership
In 2012 a first strategic alliance in the field of endometriosis was formed, that served as a very successful model recognized both internally (e.g., Bayer Drug Discovery Award 2015) and externally (e.g., ASAP Individual Alliance Excellence Award Finalist 2017), and has achieved four clinical assets so far.
Based on this initial success, Bayer and Evotec have jointly, systematically and continuously searched for additional opportunities of working together in a variety of fields and indications, covering the value chain all the way from target discovery to preclinical development.
As a result, additional joint activities in kidney diseases, heart and vascular diseases and polycystic ovary syndrome have been initiated, with additional joint activities currently still under evaluation.
In the presentation we will discuss and share:
- A systematic approach to capitalizing on an existing relationship,
- Challenges of adapting the business model of each alliance to the scope and complexity of the setup,
- Ways to enhance alliances by bringing in additional partners into an alliance ecosystem,
- Strategies for and challenges of managing to achieve repeated success.
Speakers:
Christoph Huwe, CSAP, PhD
Strategic Alliance Manager Therapeutics
Bayer AG Pharmaceuticals
Christoph has more than 20 years of experience in the pharmaceutical industry in different roles at Bayer (Germany), Berlex Biosciences (USA) and Schering AG (Germany).
He has been responsible for alliances and consortia in Europe, the US and China for more than 10 years, covering various therapeutic areas.
He is also a founding member of Bayer's Alliance Community Excellence team focussing on alliance management capability development, and has served as member of the Pharma Industry Benchmarking Forum and the EFPIA Industry Liaison Group.